Events Archives - Page 65 of 128

2 minute read

Anixa Biosciences Announces Treatment Of Second Patient In Its Ovarian Cancer CAR-T Clinical Trial

May 22, 8:35 AM

Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced

ANIX

1 minute read

ABVC BioPharma Vitargus Phase II Study Received Ethical Approval At Sydney Eye Hospital In Australia

By Happy Mohamed

May 22, 8:31 AM

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology, today announced that the

ABVC

1 minute read

Processa Pharmaceuticals To Participate In A Panel On Interaction With he FDA At The World Orphan Drug Congress

By Happy Mohamed

May 22, 8:31 AM

Company also to provide a corporate overview in a separate session HANOVER, MD, May 22, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a

PCSA

4 minute read

aTyr Pharma Presents New Data On Efzofitimod Mechanism Of Action And Exposure-Response At The American Thoracic Society 2023 International Conference

By Happy Mohamed

May 22, 8:28 AM

Advancement in mechanistic understanding of efzofitimod's modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy

LIFE

2 minute read

Pieris Pharmaceuticals Announces Presentation Of Encouraging Preclinical Data For PRS-400 At ATS 2023 International Conference

By Benzinga Newsdesk

May 22, 8:10 AM

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other

PIRS

3 minute read

Immix Biopharma Announces NXC-201 Clinical Results At ASGCT: 100% Overall Response Rate In DARZALEX-Relapsed/Refractory AL Amyloidosis With Zero ICANs In Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

By Benzinga Newsdesk

May 21, 5:24 PM

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with

IMMX

4 minute read

Teva To Present Data Demonstrating UZEDY Extended-Release Injectable Suspension Significantly Prolonged Time To Impending Relapse For Adults With Schizophrenia At The American Psychiatric Association’s 2023 Annual Meeting

By Benzinga Newsdesk

May 20, 3:49 PM

UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of risperidone1,2The U.S. Food and

TEVA

7 minute read

Alnylam Presents 18-Month Results From The APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy

By Benzinga Newsdesk

May 20, 3:48 PM

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury,

ALNY

2 minute read

Cytokinetics Presents New Data In Patients With Non-Obstructive HCM From Cohort 4 Of REDWOOD-HCM In Late-Breaking Clinical Trial Session At The European Society Of Cardiology Heart Failure 2023 Congress

By Benzinga Newsdesk

May 20, 3:46 PM

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023

ALNY

4 minute read

Abbott Unveils Late-Breaking Data Showing The World’s First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Safety And Performance Endpoints; To Present On May 19-21 At The Heart Rythm Society Annual Meeting

By Benzinga Newsdesk

May 20, 3:45 PM

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemakerThe study successfully met all three of its

ABT